“Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure” (2025) SKIN The Journal of Cutaneous Medicine, 9(1), p. s511. doi:10.25251/skin.9.supp.511.